Introduction: A Guide for Practitioners, Professionals, and Public

  • John Scott Werry
Chapter

Abstract

This chapter, more than any other, is written for nonmedical professionals and parents to introduce them to what may at first seem a dauntingly arcane field and to empower them to seek good information. It sets the scene for all the other chapters by introducing some basic terminology and concepts, most of which are familiar to prescribers. However, hopefully even they will benefit from a quick overview and reminder of things they know.

Keywords

American Psychiatric Association Psychotropic Drug Medical Knowledge Psychoactive Drug Child Psychiatry 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bradley C: The behavior of children receiving Benzedrine. Am J Orthopsychiatry 9:577–585, 1937.Google Scholar
  2. 2.
    Conners CK: Pharmacotherapy, in Quay HC, Werry JS (eds): Psychopathological Disorders of Childhood. New York, John Wiley & Sons, 1972, pp 316–347.Google Scholar
  3. 3.
    Sprague RL, Werry JS: Methodology of psychopharmacological studies in the retarded, in Ellis N (ed): International Review of Mental Retardation. New York, Academic Press, 1971, vol 5, pp 147–219.Google Scholar
  4. 4.
    American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 3. Washington, DC, American Psychiatric Association, 1980.Google Scholar
  5. 5.
    American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, DC, American Psychiatric Association, 1994.Google Scholar
  6. 6.
    Aman MG, Singh NN: Psychopharmacology of the Developmental Disabilities. Berlin, Springer, 1988.CrossRefGoogle Scholar
  7. 7.
    Lehmann HE: Strategies in clinical psychopharmacology, in Lipton MA, Di Mascio A, Killam KF (eds): Psychopharmacology: A Generation of Progress. New York, Raven Press, 1978, p 13.Google Scholar
  8. 8.
    Werry JS: Child and adolescent schizophrenia: A review in the light of DSM-III-R. J Autism Dev Disord 22:601–624, 1992.PubMedCrossRefGoogle Scholar
  9. 9.
    Weiss G, Hechtman LT: Hyperactive Children Grown Up. New York, Guilford Press, 1986, pp 240–256.Google Scholar
  10. 10.
    Efron DH: Psychopharmacology: A Review of Progress1957–1967. New York, Raven Press, 1968.Google Scholar
  11. 11.
    Werry JS, Carlielle J: The nuclear family, suburban neurosis and iatrogenesis in mothers of preschool children. J Am Acad Child Psychiatry 22:172–179, 1983PubMedCrossRefGoogle Scholar
  12. 12.
    Sulzbacher S: Psychotropic medication with children: An evaluation of procedural biases in results of reported studies. Pediatrics 51:513–517, 1973.PubMedGoogle Scholar
  13. 13.
    Schoonover SC: Introduction: The practice of pharmacotherapy, in Bassuk EL, Schoonover SC, Gelenberg AJ (eds): The Practitioner’s Guide to Psychoactive Drugs, ed 2. New York, Plenum Press, 1988, pp 1–18.Google Scholar
  14. 14.
    Kane JM: Treatment of schizophrenia. Schizophr Bull 13:147–170, 1987.CrossRefGoogle Scholar
  15. 15.
    Feagens L: A current view of learning disabilities. J Pediatr 102:487–493, 1983.CrossRefGoogle Scholar
  16. 16.
    Sprague RL, Sleator E: Methylphenidate in hyperactive children: Differences in dose effects on learning and social behavior. Science 198:1274–1276, 1977.PubMedCrossRefGoogle Scholar
  17. 17.
    Wilens TE, Spencer T, Biederman J, Wosniak J, Connor D: Combined pharmacotherapy: An emerging trend in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 34:110–112, 1995.PubMedCrossRefGoogle Scholar
  18. 18.
    Ciraulo DA, Shader RI, Greenblatt DJ, Creelman W: Drug Interactions in Psychiatry, ed 2. Baltimore, Williams and Wilkins, 1995.Google Scholar
  19. 19.
    Fenichel RR: Combining methylphenidate and Clonidine: The role of post-marketing surveillance. J Child Adolesc Psychopharmacol 5:155–156, 1995.CrossRefGoogle Scholar
  20. 20.
    Stine JJ: Psychosocial and psychodynamic issues affecting noncompliance with psychostimulant treatment. J Child Adolesc Psychopharmacol 4:75–86, 1994CrossRefGoogle Scholar
  21. 21.
    Bastiaens L: Knowledge, attitudes and compliance with pharmacotherapy in adolescent patients and their parents. J Child Adolesc Psychopharmacol 5:39–48, 1995.CrossRefGoogle Scholar
  22. 22.
    Wilson LJ, Jennings JN: Parents’ acceptability of alternative treatments for Attention-Deficit Hyperactivity Disorder. J Attention Disord, 1:114–121, 1996.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • John Scott Werry
    • 1
  1. 1.Mt. Eden, Auckland 3New Zealand

Personalised recommendations